Revised SPC: Forxiga (dapagliflozin) – all presentations

SPC –details license extension for use in symptomatic chronic heart failure with reduced ejection fraction in adults. Dapagliflozin has not been studied for the treatment of heart failure in pts with type 1 diabetes mellitus, therefore not recommended in this patient cohort.

electronic Medicines compendium